The question
Cagrilintide and CagriSema are not interchangeable names. Cagrilintide is a long-acting amylin analogue. CagriSema refers to its combination with semaglutide. That distinction matters whenever a headline attaches a weight-loss percentage to either name: evidence for a combination cannot be assigned to one component alone. Original cagrilintide trial · REDEFINE 1 publication.
The first useful step is to identify the treatment arm. The second is to identify what the reported estimate assumes. Skipping either step can turn an accurate statistic into a misleading claim.
Cagrilintide had its own clinical program
A 2021 phase 2 trial studied cagrilintide alone in adults with overweight or obesity without diabetes. It included placebo and liraglutide comparisons and a 26-week treatment period. Across the cagrilintide groups, estimated average weight reductions ranged from 6.0% to 10.8%, versus 3.0% with placebo, under an analysis assuming treatment adherence. Gastrointestinal problems and administration-site reactions were common adverse-event categories. Novo Nordisk funded the study. Original trial and author manuscript record.
This establishes that the single compound was investigated separately. It does not make every later combination result another estimate of the single compound's effect. Adding a second active treatment changes the intervention being evaluated.
REDEFINE 1 kept the arms separate
The phase 3 REDEFINE 1 trial randomized 3,417 participants to the combination, semaglutide alone, cagrilintide alone or placebo, with lifestyle intervention. At 68 weeks, the main publication reported an estimated 20.4% mean weight reduction for the combination versus 3.0% with placebo using its treatment-policy analysis. Gastrointestinal adverse events were reported in 79.6% and 39.9%, respectively. Novo Nordisk funded this trial too. Original REDEFINE 1 abstract.
Notice that the 20.4% figure belongs to the combination arm. A listing for cagrilintide alone does not inherit it. Nor does a seller establish equivalence to a trial product simply by using a familiar combination name.
Why two different percentages can both be reported
An estimand is the precisely defined treatment effect a trial is trying to estimate. In plain terms, it specifies the question behind the number—including how events such as stopping treatment are handled.
The earlier cagrilintide study reported both an approach assuming adherence and one assessing assignment regardless of adherence. These answer different questions. A treatment-policy estimate is closer to asking about the effect of being assigned a treatment strategy; an adherence-based estimate asks about an idealized treatment-use scenario. Neither label makes a result automatically more truthful. The label tells you what claim the number can support.
Imagine a hypothetical trial in which some participants stop treatment. An estimate that incorporates what happened after stopping and one that models continued treatment need not match. That difference is not a reason to select whichever percentage looks larger. It is a reason to carry the analysis label with the result.
The REDEFINE 1 registry is a useful companion to the paper when checking the treatment groups and planned outcomes. A registry entry establishes a research record; it does not establish regulatory approval.
A comparison needs more than subtraction
Subtracting results from two unrelated studies cannot isolate the effect of adding a component. Participants, follow-up, formulation and analysis can all differ. A randomized comparison within one study is better suited to that question, provided the relevant comparison and uncertainty are actually reported.
For the same reason, do not add separate percentage losses together to predict a combination. Drug effects are not a shopping-cart total. The combination has to be studied as an intervention, with its own benefits, tolerability and unanswered questions. Our tirzepatide–semaglutide explainer discusses why study context belongs beside headline results.
Current US regulatory context
As checked September 30, 2026, FDA states that cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. A positive trial does not supersede that status. FDA's current information.
When reading the next announcement, keep three labels together: the treatment, the population and the analysis. They are the difference between understanding a study and borrowing its biggest number.
Sources & further reading
Research context last reviewed September 30, 2026. Last updated October 2, 2026. Educational reading, not individual medical advice. How this article was prepared.
